



**ASX Announcement**

30 May 2024

## **2024 Annual General Meeting Results**

**Melbourne, Australia, 30 May 2024** – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001 (Cth)*, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

**For enquiries, please contact**

Melanie Leydin  
Company Secretary  
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

**About Avecho**

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (**TPM®**). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - [avecho.com.au](https://avecho.com.au)

**Annual General Meeting  
Thursday 30 May 2024  
Voting Results**

The following information is provided in accordance with section 251AA(2) of *Corporations Act 2001* (Cth) and ASX Listing Rule 3.13.2.

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution		Resolution Type	If s259U applies		For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	Carried/ Not Carried
1	Adoption of Remuneration Report	Ordinary	N/A	P	275,567,510 95.50%	8,628,270 2.99%	4,360,443 1.51%	1,488,367 -	734,153,587 98.84%	8,628,270 1.16%	1,488,367 -	Carried
2	Election of Ms Kathy Connell as a Director of the Company	Ordinary	N/A	P	288,663,757 97.89%	1,855,256 0.62%	4,393,443 1.49%	798,800 -	782,133,673 99.76%	1,855,256 0.24%	798,800 -	Carried
3	Re-Election of Dr Ross Thomas Murdoch as a Director of the Company	Ordinary	N/A	P	286,895,763 97.08%	3,152,448 1.06%	5,505,045 1.86%	158,000 -	778,343,948 99.62%	2,952,448 0.38%	3,491,333 -	Carried
4	Approval of 10% Placement Facility	Special	N/A	P	284,310,987 96.39%	6,219,175 2.10%	4,458,968 1.51%	722,126 -	777,846,428 99.21%	6,219,175 0.79%	722,126 -	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.